SEC Filing | T2 Biosystems Inc.

View:

SEC FORM 4 SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Jones Adrian M

(Last)

(First)

(Middle)

C/O GOLDMAN SACHS & CO. LLC

200 WEST STREET

(Street)

NEW YORK

10282

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
T2 Biosystems, Inc. [ TTOO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/24/2020

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock⁽¹⁾⁽²⁾⁽³⁾	03/24/2020		P		500	A	$0.378	4,196,956⁽⁴⁾⁽⁵⁾	I	See Footnotes⁽⁴⁾⁽⁵⁾
Common Stock⁽¹⁾⁽²⁾⁽³⁾	03/24/2020		S		500	D	$0.378	4,196,456⁽⁴⁾⁽⁵⁾	I	See Footnotes⁽⁴⁾⁽⁵⁾
Common Stock⁽¹⁾⁽²⁾⁽³⁾	03/25/2020		P		600	A	$0.9279	4,197,056⁽⁴⁾⁽⁵⁾	I	See Footnotes⁽⁴⁾⁽⁵⁾
Common Stock⁽¹⁾⁽²⁾⁽³⁾	03/25/2020		S		600	D	$0.9279	4,196,456⁽⁴⁾⁽⁵⁾	I	See Footnotes⁽⁴⁾⁽⁵⁾
Common Stock⁽¹⁾⁽²⁾⁽³⁾	04/09/2020		P		1,000	A	$0.49	4,197,456⁽⁴⁾⁽⁵⁾	I	See Footnotes⁽⁴⁾⁽⁵⁾
Common Stock⁽¹⁾⁽²⁾⁽³⁾	04/09/2020		S		1,000	D	$0.49	4,196,456⁽⁴⁾⁽⁵⁾	I	See Footnotes⁽⁴⁾⁽⁵⁾
Common Stock⁽¹⁾⁽²⁾⁽³⁾	05/06/2020		S		2,655	D	$0.52	4,193,801⁽⁴⁾⁽⁵⁾	I	See Footnotes⁽⁴⁾⁽⁵⁾
Common Stock⁽¹⁾⁽²⁾⁽³⁾	05/06/2020		S		1,000	D	$0.521	4,192,801⁽⁴⁾⁽⁵⁾	I	See Footnotes⁽⁴⁾⁽⁵⁾
Common Stock⁽¹⁾⁽²⁾⁽³⁾	05/06/2020		S		1,000	D	$0.526	4,191,801⁽⁴⁾⁽⁵⁾	I	See Footnotes⁽⁴⁾⁽⁵⁾
Common Stock⁽¹⁾⁽²⁾⁽³⁾	05/06/2020		S		500	D	$0.528	4,191,301⁽⁴⁾⁽⁵⁾	I	See Footnotes⁽⁴⁾⁽⁵⁾
Common Stock⁽¹⁾⁽²⁾⁽³⁾	05/06/2020		S		50	D	$0.53	4,191,251⁽⁴⁾⁽⁵⁾	I	See Footnotes⁽⁴⁾⁽⁵⁾
Common Stock⁽¹⁾⁽²⁾⁽³⁾	05/06/2020		S		500	D	$0.5318	4,190,751⁽⁴⁾⁽⁵⁾	I	See Footnotes⁽⁴⁾⁽⁵⁾
Common Stock⁽¹⁾⁽²⁾⁽³⁾	05/06/2020		S		100	D	$0.5325	4,190,651⁽⁴⁾⁽⁵⁾	I	See Footnotes⁽⁴⁾⁽⁵⁾
Common Stock⁽¹⁾⁽²⁾⁽³⁾	05/06/2020		S		6,256	D	$0.54	4,184,395⁽⁴⁾⁽⁵⁾	I	See Footnotes⁽⁴⁾⁽⁵⁾
Common Stock⁽¹⁾⁽²⁾⁽³⁾	05/06/2020		S		100	D	$0.55	4,184,295⁽⁴⁾⁽⁵⁾	I	See Footnotes⁽⁴⁾⁽⁵⁾
Common Stock⁽¹⁾⁽²⁾⁽³⁾	05/06/2020		S		939	D	$0.5503	4,183,356⁽⁴⁾⁽⁵⁾	I	See Footnotes⁽⁴⁾⁽⁵⁾
Common Stock⁽¹⁾⁽²⁾⁽³⁾	05/06/2020		P		26,200	A	$0.5517	4,209,556⁽⁴⁾⁽⁵⁾	I	See Footnotes⁽⁴⁾⁽⁵⁾
Common Stock⁽¹⁾⁽²⁾⁽³⁾	05/06/2020		S		10,100	D	$0.57	4,199,456⁽⁴⁾⁽⁵⁾	I	See Footnotes⁽⁴⁾⁽⁵⁾
Common Stock⁽¹⁾⁽²⁾⁽³⁾	05/06/2020		S		2,000	D	$0.5701	4,197,456⁽⁴⁾⁽⁵⁾	I	See Footnotes⁽⁴⁾⁽⁵⁾
Common Stock⁽¹⁾⁽²⁾⁽³⁾	05/06/2020		S		1,000	D	$0.5702	4,196,456⁽⁴⁾⁽⁵⁾	I	See Footnotes⁽⁴⁾⁽⁵⁾
Common Stock⁽¹⁾⁽²⁾⁽³⁾	05/12/2020		P		2,500	A	$0.546	4,198,956⁽⁴⁾⁽⁵⁾	I	See Footnotes⁽⁴⁾⁽⁵⁾
Common Stock⁽¹⁾⁽²⁾⁽³⁾	05/12/2020		S		2,500	D	$0.546	4,196,456⁽⁴⁾⁽⁵⁾	I	See Footnotes⁽⁴⁾⁽⁵⁾
Common Stock⁽¹⁾⁽²⁾⁽³⁾	05/19/2020		S		200	D	$0.8314	4,196,256⁽⁴⁾⁽⁵⁾	I	See Footnotes⁽⁴⁾⁽⁵⁾
Common Stock⁽¹⁾⁽²⁾⁽³⁾	05/19/2020		S		3,235	D	$0.8318	4,193,021⁽⁴⁾⁽⁵⁾	I	See Footnotes⁽⁴⁾⁽⁵⁾
Common Stock⁽¹⁾⁽²⁾⁽³⁾	05/19/2020		S		2,031	D	$0.8325	4,190,990⁽⁴⁾⁽⁵⁾	I	See Footnotes⁽⁴⁾⁽⁵⁾
Common Stock⁽¹⁾⁽²⁾⁽³⁾	05/19/2020		S		2,031	D	$0.8326	4,188,959⁽⁴⁾⁽⁵⁾	I	See Footnotes⁽⁴⁾⁽⁵⁾
Common Stock⁽¹⁾⁽²⁾⁽³⁾	05/19/2020		P		10,328	A	$0.8329	4,199,287⁽⁴⁾⁽⁵⁾	I	See Footnotes⁽⁴⁾⁽⁵⁾
Common Stock⁽¹⁾⁽²⁾⁽³⁾	05/19/2020		S		800	D	$0.8345	4,198,487⁽⁴⁾⁽⁵⁾	I	See Footnotes⁽⁴⁾⁽⁵⁾
Common Stock⁽¹⁾⁽²⁾⁽³⁾	05/19/2020		S		2,031	D	$0.8347	4,196,456⁽⁴⁾⁽⁵⁾	I	See Footnotes⁽⁴⁾⁽⁵⁾
Common Stock⁽¹⁾⁽²⁾⁽³⁾	05/20/2020		P		5,126	A	$0.803	4,201,582⁽⁴⁾⁽⁵⁾	I	See Footnotes⁽⁴⁾⁽⁵⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. These transactions in the common stock (the "Common Stock") of T2 Biosystems, Inc. (the "Issuer") have not previously been reported on Form 4 and were effected by Goldman Sachs & Co. LLC ("Goldman Sachs") acting as agent on behalf of certain international affiliates that had entered into riskless principal trades in connection with client trade facilitation in the ordinary course of their business.

2. Without conceding riskless principal trades in connection with client trade facilitation in the ordinary course of business can result in liability under Section 16(b) of the Securities Exchange Act of 1934 (the "Exchange Act"), the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer.

3. The Reporting Person is a managing director of Goldman Sachs. Goldman Sachs is a subsidiary of The Goldman Sachs Group, Inc. ("GS Group").

4. GS Group and Goldman Sachs may be deemed to beneficially own indirectly, in the aggregate, 4,157,240 shares of Common Stock of the Issuer by reason of the direct beneficial ownership of Common Stock by certain investment entities (the "GS Funds") because GS Group, or affiliates of GS Group and Goldman Sachs, are the general partner, managing general partner, managing partner, managing member or member of each of the GS Funds. Goldman Sachs beneficially owns directly and GS Group may be deemed to beneficially own indirectly 29,216 shares of common stock.

5. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of the Reporting Person's pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.

Remarks:

Balance of trades included in attached schedule. (See Exhibit 99.1)

	/s/ Jamison Yardley, Attorney-in-fact	08/03/2021
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Exhibit 99.1

EXHIBIT 99.1

Table 1 – Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security

(Instr. 3)

2. Transaction

Date

(Month/
Day/

Year)

2A.

Deemed

Execution

Date, if

any

(Month/

Day/

Year)

3. Transaction

Code

(Instr. 8)

4. Securities Acquired (A)

or Disposed of (D)

(Instr. 3, 4 and 5)

5. Amount of Securities
Beneficially Owned

Following

Reported

Transaction(s)

(Instr. 3 and 4)

6. Ownership

Form:

Direct

(D) or
Indirect

(I)

(Instr. 4)

7.
Nature of Indirect
Beneficial
Ownership

(Instr. 4)

Code (P)
or (S)

Amount

(A)

(D)

Price

Common Stock^(1)(2)(3)

05/20/2020

5,820

$ 0.8034

4,195,762⁽⁴⁾⁽⁵⁾

See Footnotes⁽⁴⁾⁽⁵⁾

Common Stock^(1)(2)(3)

05/20/2020

694

$ 0.8060

4,196,456⁽⁴⁾⁽⁵⁾

See Footnotes⁽⁴⁾⁽⁵⁾

Common Stock^(1)(2)(3)

05/26/2020

5,642

$ 0.7900

4,202,098⁽⁴⁾⁽⁵⁾

See Footnotes⁽⁴⁾⁽⁵⁾

Common Stock^(1)(2)(3)

05/26/2020

13,800

$ 0.7974

4,188,298⁽⁴⁾⁽⁵⁾

See Footnotes⁽⁴⁾⁽⁵⁾

Common Stock^(1)(2)(3)

05/26/2020

7,458

$ 0.8000

4,195,756⁽⁴⁾⁽⁵⁾

See Footnotes⁽⁴⁾⁽⁵⁾

Common Stock^(1)(2)(3)

05/26/2020

1,950

$ 0.8300

4,197,706⁽⁴⁾⁽⁵⁾

See Footnotes⁽⁴⁾⁽⁵⁾

Common Stock^(1)(2)(3)

05/26/2020

1,250

$ 0.8300

4,196,456⁽⁴⁾⁽⁵⁾

See Footnotes⁽⁴⁾⁽⁵⁾

Common Stock^(1)(2)(3)

05/28/2020

1,250

$ 0.8500

4,197,706⁽⁴⁾⁽⁵⁾

See Footnotes⁽⁴⁾⁽⁵⁾

Common Stock^(1)(2)(3)

05/28/2020

1,250

$ 0.8500

4,196,456⁽⁴⁾⁽⁵⁾

See Footnotes⁽⁴⁾⁽⁵⁾

Common Stock^(1)(2)(3)

06/03/2020

1,781

$ 1.0700

4,198,237⁽⁴⁾⁽⁵⁾

See Footnotes⁽⁴⁾⁽⁵⁾

Common Stock^(1)(2)(3)

06/03/2020

200

$ 1.0900

4,198,437⁽⁴⁾⁽⁵⁾

See Footnotes⁽⁴⁾⁽⁵⁾

Common Stock^(1)(2)(3)

06/03/2020

1,051

$ 1.1000

4,199,488⁽⁴⁾⁽⁵⁾

See Footnotes⁽⁴⁾⁽⁵⁾

Common Stock^(1)(2)(3)

06/03/2020

10,000

$ 1.1314

4,189,488⁽⁴⁾⁽⁵⁾

See Footnotes⁽⁴⁾⁽⁵⁾

Common Stock^(1)(2)(3)

06/03/2020

4,835

$ 1.1500

4,194,323⁽⁴⁾⁽⁵⁾

See Footnotes⁽⁴⁾⁽⁵⁾

Common Stock^(1)(2)(3)

06/03/2020

2,133

$ 1.1600

4,196,456⁽⁴⁾⁽⁵⁾

See Footnotes⁽⁴⁾⁽⁵⁾

Common Stock^(1)(2)(3)

06/04/2020

7,500

$ 1.2900

4,203,956⁽⁴⁾⁽⁵⁾

See Footnotes⁽⁴⁾⁽⁵⁾

Common Stock^(1)(2)(3)

06/04/2020

7,500

$ 1.2900

4,196,456⁽⁴⁾⁽⁵⁾

See Footnotes⁽⁴⁾⁽⁵⁾

Common Stock^(1)(2)(3)

06/08/2020

3,200

$ 1.3400

4,199,656⁽⁴⁾⁽⁵⁾

See Footnotes⁽⁴⁾⁽⁵⁾

Common Stock^(1)(2)(3)

06/08/2020

5,474

$ 1.3442

4,194,182⁽⁴⁾⁽⁵⁾

See Footnotes⁽⁴⁾⁽⁵⁾

Common Stock^(1)(2)(3)

06/08/2020

2,274

$ 1.3500

4,196,456⁽⁴⁾⁽⁵⁾

See Footnotes⁽⁴⁾⁽⁵⁾

Common Stock^(1)(2)(3)

06/09/2020

200

$ 1.2900

4,196,256⁽⁴⁾⁽⁵⁾

See Footnotes⁽⁴⁾⁽⁵⁾

Common Stock^(1)(2)(3)

06/09/2020

38,963

$ 1.3629

4,235,219⁽⁴⁾⁽⁵⁾

See Footnotes⁽⁴⁾⁽⁵⁾

Common Stock^(1)(2)(3)

06/09/2020

38,963

$ 1.3629

4,196,256⁽⁴⁾⁽⁵⁾

See Footnotes⁽⁴⁾⁽⁵⁾

Common Stock^(1)(2)(3)

06/09/2020

3,800

$ 1.3633

4,200,056⁽⁴⁾⁽⁵⁾

See Footnotes⁽⁴⁾⁽⁵⁾

Common Stock^(1)(2)(3)

06/09/2020

3,600

$ 1.3674

4,196,456⁽⁴⁾⁽⁵⁾

See Footnotes⁽⁴⁾⁽⁵⁾

Common Stock^(1)(2)(3)

06/10/2020

163,073

$ 1.7000

4,359,529⁽⁴⁾⁽⁵⁾

See Footnotes⁽⁴⁾⁽⁵⁾

Common Stock^(1)(2)(3)

06/10/2020

163,073

$ 1.7000

4,196,456⁽⁴⁾⁽⁵⁾

See Footnotes⁽⁴⁾⁽⁵⁾

Common Stock^(1)(2)(3)

06/10/2020

163,073

$ 1.7317

4,359,529⁽⁴⁾⁽⁵⁾

See Footnotes⁽⁴⁾⁽⁵⁾

Common Stock^(1)(2)(3)

06/10/2020

163,073

$ 1.7317

4,196,456⁽⁴⁾⁽⁵⁾

See Footnotes⁽⁴⁾⁽⁵⁾

Common Stock^(1)(2)(3)

06/11/2020

2,000

$ 1.5000

4,194,456⁽⁴⁾⁽⁵⁾

See Footnotes⁽⁴⁾⁽⁵⁾

Common Stock^(1)(2)(3)

06/11/2020

2,000

$ 1.5300

4,196,456⁽⁴⁾⁽⁵⁾

See Footnotes⁽⁴⁾⁽⁵⁾

Common Stock^(1)(2)(3)

06/11/2020

2,000

$ 1.5300

4,194,456⁽⁴⁾⁽⁵⁾

See Footnotes⁽⁴⁾⁽⁵⁾

Common Stock^(1)(2)(3)

06/11/2020

300

$ 1.5800

4,194,156⁽⁴⁾⁽⁵⁾

See Footnotes⁽⁴⁾⁽⁵⁾

Common Stock^(1)(2)(3)

06/11/2020

46,050

$ 1.5955

4,240,206⁽⁴⁾⁽⁵⁾

See Footnotes⁽⁴⁾⁽⁵⁾

Common Stock^(1)(2)(3)

06/11/2020

43,750

$ 1.6000

4,196,456⁽⁴⁾⁽⁵⁾

See Footnotes⁽⁴⁾⁽⁵⁾

Common Stock^(1)(2)(3)

06/15/2020

47,750

$ 1.6100

4,234,206⁽⁴⁾⁽⁵⁾

See Footnotes⁽⁴⁾⁽⁵⁾

Common Stock^(1)(2)(3)

06/15/2020

47,750

$ 1.6100

4,186,456⁽⁴⁾⁽⁵⁾

See Footnotes⁽⁴⁾⁽⁵⁾

Common Stock^(1)(2)(3)

06/16/2020

2,000

$ 1.5000

4,188,456⁽⁴⁾⁽⁵⁾

See Footnotes⁽⁴⁾⁽⁵⁾

Common Stock^(1)(2)(3)

06/16/2020

2,000

$ 1.5000

4,186,456⁽⁴⁾⁽⁵⁾

See Footnotes⁽⁴⁾⁽⁵⁾

Common Stock^(1)(2)(3)

06/17/2020

708

$ 1.4410

4,185,748⁽⁴⁾⁽⁵⁾

See Footnotes⁽⁴⁾⁽⁵⁾

Common Stock^(1)(2)(3)

06/17/2020

2,708

$ 1.4476

4,188,456⁽⁴⁾⁽⁵⁾

See Footnotes⁽⁴⁾⁽⁵⁾

Common Stock^(1)(2)(3)

06/17/2020

2,000

$ 1.4500

4,186,456⁽⁴⁾⁽⁵⁾

See Footnotes⁽⁴⁾⁽⁵⁾

Common Stock^(1)(2)(3)

06/29/2020

300

$ 1.2900

4,186,756⁽⁴⁾⁽⁵⁾

See Footnotes⁽⁴⁾⁽⁵⁾

Common Stock^(1)(2)(3)

06/29/2020

300

$ 1.2900

4,186,456⁽⁴⁾⁽⁵⁾

See Footnotes⁽⁴⁾⁽⁵⁾

Common Stock^(1)(2)(3)

06/29/2020

3,973

$ 1.3300

4,190,429⁽⁴⁾⁽⁵⁾

See Footnotes⁽⁴⁾⁽⁵⁾

Common Stock^(1)(2)(3)

06/29/2020

5,000

$ 1.3341

4,185,429⁽⁴⁾⁽⁵⁾

See Footnotes⁽⁴⁾⁽⁵⁾

Common Stock^(1)(2)(3)

06/29/2020

1,027

$ 1.3500

4,186,456⁽⁴⁾⁽⁵⁾

See Footnotes⁽⁴⁾⁽⁵⁾

Common Stock^(1)(2)(3)

07/01/2020

250,000

$ 1.7542

4,436,456⁽⁴⁾⁽⁵⁾

See Footnotes⁽⁴⁾⁽⁵⁾

Common Stock^(1)(2)(3)

07/01/2020

250,000

$ 1.7542

4,186,456⁽⁴⁾⁽⁵⁾

See Footnotes⁽⁴⁾⁽⁵⁾

Common Stock^(1)(2)(3)

07/01/2020

47,586

$ 1.9254

4,234,042⁽⁴⁾⁽⁵⁾

See Footnotes⁽⁴⁾⁽⁵⁾

Common Stock^(1)(2)(3)

07/01/2020

250,000

$ 1.9362

4,484,042⁽⁴⁾⁽⁵⁾

See Footnotes⁽⁴⁾⁽⁵⁾

Common Stock^(1)(2)(3)

07/01/2020

297,586

$ 1.9345

4,186,456⁽⁴⁾⁽⁵⁾

See Footnotes⁽⁴⁾⁽⁵⁾

Common Stock^(1)(2)(3)

07/07/2020

350

$ 1.2400

4,186,806⁽⁴⁾⁽⁵⁾

See Footnotes⁽⁴⁾⁽⁵⁾

Common Stock^(1)(2)(3)

07/07/2020

350

$ 1.2400

4,186,456⁽⁴⁾⁽⁵⁾

See Footnotes⁽⁴⁾⁽⁵⁾

Common Stock^(1)(2)(3)

07/08/2020

$ 1.2900

4,186,406⁽⁴⁾⁽⁵⁾

See Footnotes⁽⁴⁾⁽⁵⁾

Common Stock^(1)(2)(3)

07/08/2020

350

$ 1.2943

4,186,756⁽⁴⁾⁽⁵⁾

See Footnotes⁽⁴⁾⁽⁵⁾

Common Stock^(1)(2)(3)

07/08/2020

300

$ 1.2950

4,186,456⁽⁴⁾⁽⁵⁾

See Footnotes⁽⁴⁾⁽⁵⁾

Common Stock^(1)(2)(3)

07/21/2020

500

$ 1.7400

4,267,807⁽⁴⁾⁽⁵⁾

See Footnotes⁽⁴⁾⁽⁵⁾

Common Stock^(1)(2)(3)

07/21/2020

500

$ 1.7400

4,267,307⁽⁴⁾⁽⁵⁾

See Footnotes⁽⁴⁾⁽⁵⁾

Common Stock^(1)(2)(3)

07/22/2020

1,500

$ 1.6813

4,187,956⁽⁴⁾⁽⁵⁾

See Footnotes⁽⁴⁾⁽⁵⁾

Common Stock^(1)(2)(3)

07/22/2020

1,500

$ 1.6813

4,186,456⁽⁴⁾⁽⁵⁾

See Footnotes⁽⁴⁾⁽⁵⁾

Common Stock^(1)(2)(3)

07/23/2020

3,000

$ 1.6883

4,189,456⁽⁴⁾⁽⁵⁾

See Footnotes⁽⁴⁾⁽⁵⁾

Common Stock^(1)(2)(3)

07/23/2020

3,000

$ 1.6883

4,186,456⁽⁴⁾⁽⁵⁾

See Footnotes⁽⁴⁾⁽⁵⁾

Common Stock^(1)(2)(3)

07/24/2020

7,500

$ 1.5500

4,193,956⁽⁴⁾⁽⁵⁾

See Footnotes⁽⁴⁾⁽⁵⁾

Common Stock^(1)(2)(3)

07/24/2020

8,211

$ 1.5508

4,185,745⁽⁴⁾⁽⁵⁾

See Footnotes⁽⁴⁾⁽⁵⁾

Common Stock^(1)(2)(3)

07/24/2020

100

$ 1.5550

4,185,845⁽⁴⁾⁽⁵⁾

See Footnotes⁽⁴⁾⁽⁵⁾

Common Stock^(1)(2)(3)

07/24/2020

611

$ 1.5600

4,186,456⁽⁴⁾⁽⁵⁾

See Footnotes⁽⁴⁾⁽⁵⁾

Common Stock^(1)(2)(3)

07/28/2020

7,523

$ 1.4800

4,193,979⁽⁴⁾⁽⁵⁾

See Footnotes⁽⁴⁾⁽⁵⁾

Common Stock^(1)(2)(3)

07/28/2020

7,523

$ 1.4800

4,186,456⁽⁴⁾⁽⁵⁾

See Footnotes⁽⁴⁾⁽⁵⁾

Common Stock^(1)(2)(3)

08/03/2020

46,565

$ 1.6473

4,233,021⁽⁴⁾⁽⁵⁾

See Footnotes⁽⁴⁾⁽⁵⁾

Common Stock^(1)(2)(3)

08/03/2020

46,565

$ 1.6473

4,186,456⁽⁴⁾⁽⁵⁾

See Footnotes⁽⁴⁾⁽⁵⁾

Explanation of Responses:

These transactions in the common stock (the “Common Stock”) of T2 Biosystems, Inc. (the “Issuer”) have not previously been reported on Form 4 and were effected by Goldman Sachs & Co. LLC (“Goldman Sachs”) acting as agent on behalf of certain international affiliates that had entered into riskless principal trades in connection with client trade facilitation in the ordinary course of their business.

Without conceding riskless principal trades in connection with client trade facilitation in the ordinary course of business can result in liability under Section 16(b) of the Securities Exchange Act of 1934 (the “Exchange Act”), the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer.

3.	The Reporting Person is a managing director of Goldman Sachs. Goldman Sachs is a subsidiary of The Goldman Sachs Group, Inc. (“GS Group”).

GS Group and Goldman Sachs may be deemed to beneficially own indirectly, in the aggregate, 4,157,240 shares of Common Stock of the Issuer by reason of the direct beneficial ownership of Common Stock by certain investment entities (the “GS Funds”) because GS Group, or affiliates of GS Group and Goldman Sachs, are the general partner, managing general partner, managing partner, managing member or member of each of the GS Funds. Goldman Sachs beneficially owns directly and GS Group may be deemed to beneficially own indirectly 29,216 shares of common stock.

The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of the Reporting Person’s pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.